[Results of in vivo analysis of injected fibrinogen degradation products and factor VIII in patients with hemophilia A].
Seven patients with haemophilia A CP were injected in a dosage of 1 to 3 double units, which were stored for 127 days partly deep-frozen, partly lyophilized and after this time contained fibrinogen fission products (16--256 microgram/ml). Though in two patients after the transfusion positive WA of the injected fibrinogen fission products were established, a relevant influence on the fibrinogen fission product levels of the patients is to be expected only after administration of larger quantities of such preparations. The therapeutic efficacy of the stored CP was insufficient, since despite good in-vitro-activities of factor VIII the increase of factor VIII in four patients was slight and retarding and did not take place in three patients.
D001793:Blood Preservation; D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans
D005338:Fibrin Fibrinogen Degradation Products; D005169:Factor VIII
Ergebnisse der In-vivo-Wiederauffindung von Fibrinogenspaltprodukten und Fakto VIII bei Patienten mit Hämophilie A.